Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?

Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.

Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)

Hosted on Acast. See acast.com/privacy for more information.